Cytomegalovirus Disease After Liver Transplant—A Description of a Treatment-Resistant Case: A Case Report and Literature Review

2018 ◽  
Vol 50 (10) ◽  
pp. 4015-4022 ◽  
Author(s):  
P. Czarnecka ◽  
K. Czarnecka ◽  
O. Tronina ◽  
M. Durlik
BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S115-S115
Author(s):  
Ciara Clarke ◽  
Clodagh Rushe ◽  
Fintan Byrne

ObjectiveWe report a case of a 58-year-old gentleman who was hospitalised intermittently for one year due to treatment resistant schizophrenia. Prior to hospitalisation he had been prescribed standard antipsychotics for decades without full resolution of positive psychotic symptoms. During his final admission lasting six months he was guarded, suspicious, irritable, constantly paced the corridor and displayed thought block and paranoid persecutory delusions. He would not enter the assessment room or allow any blood or ECG monitoring, however, he was compliant with oral medication. He was successfully treated with high dose olanzapine (40mg/day) and was discharged to the community. The aim of this study is to bring awareness and add to the body of evidence for the use of high-dose olanzapine in patients with treatment resistant schizophrenia in whom a trial of clozapine is not possible.Case reportThe patient gave written consent for this case report to be written and presented. An extensive literature review was performed and key papers were identified. Discussion focuses on the key areas in the literature.DiscussionThis case demonstrates that high-dose olanzapine can be used effectively as an alternative to clozapine in treatment resistant schizophrenia.ConclusionThis case highlights the need for further evaluation of high-dose olanzapine as an alternative to clozapine in patients with treatment-resistant schizophrenia.


2018 ◽  
Vol 184 (1) ◽  
pp. 177-180 ◽  
Author(s):  
Pakpoom Phoompoung ◽  
Methee Chayakulkeeree ◽  
Popchai Ngamskulrungroj ◽  
Ananya Pongpaibul

2013 ◽  
Vol 36 (5) ◽  
pp. 367-372 ◽  
Author(s):  
Maria Francesca Donato ◽  
Giovanni Banfi ◽  
Donata Cresseri ◽  
G. Battista Fogazzi ◽  
Paul Martin ◽  
...  

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e543
Author(s):  
J.O. Varaschin Zeni ◽  
A. Vinholi ◽  
H.N. Rasera ◽  
G.P. Ramos ◽  
L.M. Sarquis ◽  
...  

2020 ◽  
Vol 1 (5) ◽  
pp. 20-24
Author(s):  
Alaina Giacobbe ◽  
Mitesh Patel ◽  
Scott Heller ◽  
Miguel Chuquilin

Objectives:  To describe a case of rapidly relapsing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in the setting of positive serum IgG tubulin autoantibodies. Methods: We wrote a case report and performed a literature review of IgG tubulin autoantibodies and the use of rituximab in treatment resistant CIDP. Results: Our case report describes a 29-year-old woman with CIDP that was resistant to treatment with steroids, intravenous immunoglobulin, and plasma exchange. An extensive workup of her rapidly relapsing CIDP was negative, with the exception of positive serum IgG tubulin autoantibodies. She ultimately stabilized on oral steroids, plasma exchange and rituximab, with a regular recurrence of weakness occurring approximately every month that led to rehospitalization. Conclusion: Anti-tubulin antibodies could be a marker of a subtype of CIDP that is treatment resistant. We detail her clinical course to serve as an example for other cases of IgG tubulin autoantibody positive CIDP patients that could be described in the future.


Sign in / Sign up

Export Citation Format

Share Document